Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Probiotics in the management of inflammatory bowel disease.

Literature DB >> 16369245

Probiotics in the management of inflammatory bowel disease.

Robert M Penner¹, Richard N Fedorak.

Abstract

Entities: Disease

Mesh：

Year: 2005 PMID： 16369245 PMCID： PMC1681665

Source DB: PubMed Journal: MedGenMed ISSN： 1531-0132

× No keyword cloud information.

21 in total

1. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors: T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal: Gut Date: 2004-01 Impact factor: 23.059

2. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors: Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal: Gastroenterology Date: 2003-05 Impact factor: 22.682

3. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis.

Authors: K O Laake; P D Line; L Aabakken; T Løtveit; A Bakka; J Eide; A Roseth; K Grzyb; A Bjørneklett; M H Vatn
Journal: Scand J Gastroenterol Date: 2003-04 Impact factor: 2.423

4. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

Authors: C Prantera; M L Scribano; G Falasco; A Andreoli; C Luzi
Journal: Gut Date: 2002-09 Impact factor: 23.059

5. A pilot trial of Saccharomyces boulardii in ulcerative colitis.

Authors: Mario Guslandi; Patrizia Giollo; Pier Alberto Testoni
Journal: Eur J Gastroenterol Hepatol Date: 2003-06 Impact factor: 2.566

6. Pouchitis: result of microbial imbalance?

Authors: J G Ruseler-van Embden; W R Schouten; L M van Lieshout
Journal: Gut Date: 1994-05 Impact factor: 23.059

7. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

Authors: Martijn P Gosselink; W Rudolph Schouten; Leo M C van Lieshout; Willem C J Hop; Jon D Laman; Johanneke G H Ruseler-van Embden
Journal: Dis Colon Rectum Date: 2004-04-19 Impact factor: 4.585

8. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

Authors: W Kruis; P Fric; J Pokrotnieks; M Lukás; B Fixa; M Kascák; M A Kamm; J Weismueller; C Beglinger; M Stolte; C Wolff; J Schulze
Journal: Gut Date: 2004-11 Impact factor: 23.059

Probiotics in the management of inflammatory bowel disease.

1. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

2. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

3. Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis.

4. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

5. A pilot trial of Saccharomyces boulardii in ulcerative colitis.

6. Pouchitis: result of microbial imbalance?

7. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG.

8. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.

9. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.

10. Lactobacillus GG in inducing and maintaining remission of Crohn's disease.

Review 1. Functional foods and their role in cancer prevention and health promotion: a comprehensive review.

2. Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics.